Efficacy of Adjunctive Low-Level Light Therapy to Intense Pulsed Light for Meibomian Gland Dysfunction

NARecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
MGD-Meibomian Gland Dysfunction
Interventions
DEVICE

Low-level light therapy (LLLT)

LLLT therapy will be delivered using the Light Modulation® special facial mask (Espansione Marketing S.p.A., Bologna, Italy) which will be placed on the participant's face for 15 minutes. The mask has the shape of a half-face and will emit a red light in an LED system. The device has an emission power of 100 The mask has the shape of a half-face and will emit a red light in a light-emitting diode (LED) system. The device has an emission power of 100 milliwatts per square centimeter.

DEVICE

Intense pulsed light (IPL)

The IPL therapy will be performed using the Eye-light® with Optimal Power Energy® (Espansione Marketing S.p.A., Bologna, Italy), which emits the light at a wavelength of 600 nm IPL system with fluence ranging from 10 to 16 J/cm2 per eye depending on the Fitzpatrick skin scale. During IPL treatment 5 flashes of light will be applied to the skin around the eye using a handheld device; 3 along the inferior orbital rim, 1 at the lateral canthus, and 1 applied horizontally along the inferior orbital rim

Trial Locations (1)

10330

RECRUITING

King Chulalongkorn memorial hospital, Bangkok

All Listed Sponsors
lead

Chulalongkorn University

OTHER